Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)

NCT07309757 | Not Yet Recruiting

• 1 other identifier: STUDY00028946
• Study Type: observational
• Target: 35
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.

Conditions

Methamphetamine Abuse

Keywords

Methamphetamine use; Pregnancy; Cardiomyopathy

Outcome Measures

Primary Outcomes (1)

• Sensitivity of point of care cardiac ultrasound for the detection of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram.

  This outcome seeks to identify the sensitivity of point of care cardiac ultrasound for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine when performed by an obstetrics provider, as compared to formal transthoracic echocardiogram.

  Day 1

Secondary Outcomes (4)

• Sensitivity of cardiac biomarkers and ECG for the identification of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram. methamphetamine

  Day 1

• Prevalence of underlying structural heart disease in pregnant people who use methamphetamine

  Day 1

• Pregnancy and delivery outcomes in people who use methamphetamine

  3 months postpartum

• Changes to pregnancy-related treatment plan based on cardiovascular screening in people who use methamphetamine.

  3 months postpartum

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: female
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Pregnant women \> or equal to 20 weeks gestation presenting to OHSU for hospital, day patient, or observation admission will be identified via the electronic medical record.

You may qualify if:

• years or older \> 20 weeks gestation admitted to the hospital
• Active patient-defined regular methamphetamine use for at least 1 year and any use within the last month
• Able to understand and provide informed consent
• Able to understand English

You may not qualify if:

• These criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.
• Prescribed stimulants
• Echocardiogram or EKG previously performed during current pregnancy
• Previous diagnosis of congestive heart dysfunction
• Previous diagnosis of pulmonary hypertension
• Previous myocardial infarction
• Previous diagnosis of endocarditis
• Prior cardiac intervention (repair of cardiac congenital lesion, valve replacement or repairs, percutaneous/operative treatment of arrhythmias)
• High-risk aortopathy (Marfan syndrome, bicuspid aortopathy, prior aortic dissection)

Sponsors & Collaborators

• Oregon Health and Science University: lead

MeSH Terms

Conditions

Cardiomyopathies

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Central Study Contacts

Evan Shalen, MD

CONTACT

503-494-1775; shalen@ohsu.edu

Sara McCrimmon

CONTACT

mccrimmo@ohsu.edu

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: December 16, 2025
• First Posted: December 30, 2025
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share